ImmuCell Corporation

NasdaqCM:ICCC

Sector

🛒 Consumer Staples

Industries

🍔 Meat

🔬 Clinical Trials

🥛 Dairy & Milk

🐶 Pet Food

💉 Vaccines

Location

United States

Market Cap

USD 63.09 M

Share Price

USD 6.75

Avg Daily Volume

27,368

Change (1 day)

-0.59%

Change (1 year)

54.82%

Change (YTD)

31.07%

ImmuCell Corporation Net Income for the Trailing 12 Months (TTM) ending March 31, 2025

ImmuCell Corporation Net Income is NA for the Trailing 12 Months (TTM) ending March 31, 2025. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

ImmuCell Corporation Net Income for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -5.32 M, a -584.30% change year over year.
ImmuCell Corporation Net Income for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 1.10 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Selling, General, and Administrative Expenses (SG&A)

NasdaqCM: ICCC

ImmuCell Corporation

CEO	Mr. Michael F. Brigham
IPO Date	May 5, 1987
Location	United States
Headquarters	56 Evergreen Drive
Employees	69
Sector	🛒 Consumer Staples
Industries Meat 🔬 Clinical Trials 🥛 Dairy & Milk 🐶 Pet Food 💉 Vaccines

Description

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.